|
PM20D2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.60520485792404E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.09770000259013E-08 |
| Normal-vs-Stage2 |
6.4019000001192E-07 |
| Normal-vs-Stage3 |
1.12040376976097E-11 |
| Normal-vs-Stage4 |
1.01990005330066E-09 |
| Stage1-vs-Stage2 |
2.319400E-01 |
| Stage1-vs-Stage3 |
1.693760E-02 |
| Stage1-vs-Stage4 |
3.066400E-02 |
| Stage2-vs-Stage3 |
6.992600E-01 |
| Stage2-vs-Stage4 |
4.664600E-01 |
| Stage3-vs-Stage4 |
6.087000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.87240231600094E-11 |
| Normal-vs-AfricanAmerican |
4.278600E-03 |
| Normal-vs-Asian |
1.239330E-04 |
| Caucasian-vs-AfricanAmerican |
2.578600E-01 |
| Caucasian-vs-Asian |
2.381400E-01 |
| AfricanAmerican-vs-Asian |
8.380000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.36020133729198E-11 |
| Normal-vs-Female |
3.42309958156761E-10 |
| Male-vs-Female |
3.308600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.55709999969534E-07 |
| Normal-vs-Age(41-60Yrs) |
1.91220039802431E-10 |
| Normal-vs-Age(61-80Yrs) |
4.42856862292729E-12 |
| Normal-vs-Age(81-100Yrs) |
1.435650E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.370100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.644500E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.585800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.532020E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.831400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.714200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.956300E-04 |
| Classical-VS-Follicular |
5.435400E-04 |
| Classical-VS-Other |
7.164600E-01 |
| Classical-VS-Normal |
2.65649999775519E-08 |
| Tall-VS-Follicular |
7.389400E-01 |
| Tall-VS-Other |
2.647200E-01 |
| Tall-VS-Normal |
3.73090003336074E-10 |
| Follicular-VS-Other |
2.983000E-01 |
| Follicular-VS-Normal |
2.50000020685093E-11 |
| Other-VS-Normal |
1.569020E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.25549570739736E-11 |
| Normal-vs-N1 |
8.62579999649782E-08 |
| N0-vs-N1 |
9.763800E-01 |
|
|
